Mixed views on Broad’s fate after EPO revokes CRISPR patent – Life Sciences Intellectual Property Review
Life Sciences Intellectual Property Review |
Mixed views on Broad's fate after EPO revokes CRISPR patent
Life Sciences Intellectual Property Review Daniel Lim, senior associate at Allen & Overy, attended the hearing at the EPO. He has since told LSIPR that while some of Broad's other opposed CRISPR patents will be vulnerable to revocation based on lack of priority, the institute does have other … |
